



## (omalizumab) for subcutaneous use

## **SAMPLE CODING**

## **Moderate to Severe Persistent Allergic Asthma**

ТҮРЕ	CODE		DESCRIPTION
Diagnosis: ICD-10-CM	J45.40		Moderate persistent asthma, uncomplicated
	J45.50		Severe persistent asthma, uncomplicated
Drug: NDC  Note: Payer requirements regarding use of a 10-digit or 11- digit NDC may vary. Both formats are listed here for your reference.	10-digit	11-digit	
	50242-214-01	50242-0214-01	75-mg Prefilled Syringe
	50242-215-01	50242-0215-01	150-mg Prefilled Syringe
	50242-040-62	50242-0040-62	150-mg single-dose Vial
	50242-227-01	50242-0227-01	300-mg Prefilled Syringe
	50242-214-55	50242-0214-55	75-mg Autoinjector
	50242-215-55	50242-0215-55	150-mg Autoinjector
	50242-227-55	50242-0227-55	300-mg Autoinjector
Drug: HCPCS	J2357		Injection, omalizumab, 5 mg*
HCPCS: Modifier <sup>†</sup> Note: As of July 1, 2023, CMS requires the use of the JZ modifier to indicate there were no units of a drug discarded.	JW		Drug amount discarded/not administered to any patient
	JZ		Zero drug amount discarded/not administered to any patient
Administration procedures: CPT	96372		Therapeutic, prophylactic or diagnostic injection (specify substance or drug); subcutaneous or intramuscular

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech and Novartis do not make any representation or guarantee concerning reimbursement or coverage for any item or service.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Please see full Prescribing Information, including Boxed WARNING and Medication Guide, for Important Safety Information.

<sup>\*</sup>Applies to all NDC codes for XOLAIR.

Per CMS, the JW modifier is required on claims for all single-dose container or single-use drugs when an amount is discarded and may be used for weight-based indications in cases where partial units or not administered drug are discarded. CMS also requires the JZ modifier to be used on claims for all single-dose containers or single-use drugs when no drug is discarded/administered to any patient as of July 1, 2023. For more information on the JW and JZ modifiers, visit CMS.gov.